Table 2 Methylation status of DACT1 and DACT2 in ESCC cases
Group | N | DACT1 (region 1) | DACT1 (region 2) | DACT2 | Simultaneous methylation of DACT1 and DACT2 | ||||
|---|---|---|---|---|---|---|---|---|---|
M (%) | p | M (%) | p | M (%) | p | M (%) | p | ||
Age | |||||||||
 <60 | 74 | 39(52.7%) | 0.744 | 32(43.2%) | 0.283 | 39(52.7%) | 0.906 | 23(31.1%) | 0.574 |
 ≥60 | 85 | 47(55.3%) |  | 44(51.8%) |  | 44(51.8%) |  | 30(35.3%) |  |
Gender | |||||||||
 Male | 93 | 48(51.6%) | 0.457 | 40(43.0%) | 0.151 | 47(50.5%) | 0.618 | 35(37.6%) | 0.550 |
 Female | 66 | 38(57.6%) |  | 36(54.5%) |  | 36(54.5%) |  | 18(27.3%) |  |
Histological grade | |||||||||
 Well/moderate | 98 | 49(50.0%) | 0.190 | 41(41.8%) | 0.056 | 46(46.9%) | 0.092 | 28(28.6%) | 0.106 |
 Poor | 61 | 37(60.7%) |  | 35(57.4%) |  | 37(60.7%) |  | 25(41.0%) |  |
Clinical stage | |||||||||
 I + II | 86 | 46(53.5%) | 0.869 | 35(40.7%) | 0.052 | 39(45.3%) | 0.060 | 22(25.6%) | 0.015 |
 III + IV | 73 | 40(54.8%) |  | 41(56.2%) |  | 44(60.3%) |  | 32(43.8%) |  |
Lymph node | |||||||||
 + | 121 | 70(57.9%) | 0.089 | 63(52.1%) | 0.055 | 67(55.4%) | 0.153 | 48(39.7%) | 0.001 |
 - | 38 | 16(42.1%) |  | 13(34.2%) |  | 16(42.1%) |  | 4(10.5%) |  |
Family history of UGIC | |||||||||
 + | 61 | 38(62.3%) | 0.101 | 36(59.0%) | 0.025 | 40(65.6%) | 0.008 | 29(47.5%) | 0.004 |
 - | 98 | 48(49.0%) |  | 40(40.8%) |  | 43(43.9%) |  | 25(25.5%) |  |